

Yoshimasa Aso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7472993/publications.pdf>

Version: 2024-02-01

81
papers

2,834
citations

201674

27
h-index

182427

51
g-index

88
all docs

88
docs citations

88
times ranked

3896
citing authors

#	ARTICLE	IF	CITATIONS
1	Updates in diabetic neuropathy: A call for new diagnostic and treatment approaches. <i>Journal of Diabetes Investigation</i> , 2022, 13, 432-434.	2.4	4
2	Acute Exacerbation of Anemia with Parvovirus B19 Infection One Year after Sleeve Gastrectomy for Severe Obesity. <i>Internal Medicine</i> , 2022, , .	0.7	0
3	Switching from the tablet to the powder formulation of levothyroxine corrects severe hypothyroidism in a patient with lactose intolerance. <i>Endocrine Journal</i> , 2022, 69, 941-945.	1.6	3
4	Synergistic effects of liver fibrosis and sarcopenia on endothelial dysfunction and arterial stiffness in patients with type 2 diabetes. <i>IJC Heart and Vasculature</i> , 2022, 41, 101071.	1.1	0
5	Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) coâ€formulation therapy twiceâ€daily with free combination of GLPâ€1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial. <i>International Journal of Clinical Practice</i> , 2021, 75, e13734.	1.7	4
6	Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol. <i>International Journal of Cardiology</i> , 2021, 331, 243-248.	1.7	18
7	Intensive risk factor management and cardiovascular autonomic neuropathy in type 2 diabetes in the Action to Control Cardiovascular Risk in Diabetes trial: A postâ€hoc analysis. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1316-1318.	2.4	4
8	Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107885.	2.3	7
9	Serum high-molecular-weight adiponectin and response to dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease. <i>Journal of Investigative Medicine</i> , 2021, 69, 1324-1329.	1.6	4
10	No Negative Impact of a National State of Emergency by COVID-19 Outbreak on Hemoglobin A1c Levels in Patients With Type 2 Diabetes Living in Semi-Rural Japan. <i>American Journal of the Medical Sciences</i> , 2021, 362, 104-105.	1.1	7
11	Acute effect of addâ€on therapy with tofogliflozin, a sodium glucose coâ€transporter 2 inhibitor, on 24â€hours glucose profile and glycaemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidaseâ€4 inhibitors. <i>International Journal of Clinical Practice</i> , 2021, 75, e14732.	1.7	2
12	Symptomatic hypocalcemia after treatment for hyperthyroidism in a woman with chromosome 22q11.2 deletion syndrome complicated by Gravesâ€ disease: longitudinal changes in the number of subsets of CD4 and CD8 lymphocytes after thyroidectomy. <i>Endocrine Journal</i> , 2021, 68, 1187-1195.	1.6	1
13	Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107703.	2.3	23
14	Bullous pemphigoid associated with dipeptidyl peptidaseâ€4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 2007-2012.	0.5	2
15	CDâ€1^{db/db} mice: A novel type 2 diabetic mouse model with progressive kidney fibrosis. <i>Journal of Diabetes Investigation</i> , 2020, 11, 1470-1481.	2.4	5
16	Teneligliptin, a DPP-4 Inhibitor, Decreases Plasma Levels of Inflammatory Chemokines During a Standard Meal Test in Patients With Type 2 Diabetes. <i>American Journal of the Medical Sciences</i> , 2020, 360, 261-267.	1.1	6
17	Genetic alteration of ARMC5 in a patient diagnosed with meningioma and primary macronodular adrenal hyperplasia: a case report. <i>European Journal of Endocrinology</i> , 2020, 183, K7-K12.	3.7	13
18	The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5237.	4.1	68

#	ARTICLE	IF	CITATIONS
19	Denosumab improves clinical manifestations of hypophosphatemic osteomalacia by adefovir-induced Fanconi syndrome: a case report. <i>Journal of Medical Case Reports</i> , 2019, 13, 99.	0.8	6
20	Macrophage-specific hypoxia-inducible factor-1 β deletion suppresses the development of liver tumors in high-fat diet-fed obese and diabetic mice. <i>Journal of Diabetes Investigation</i> , 2019, 10, 1411-1418.	2.4	4
21	Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease. <i>International Journal of Clinical Practice</i> , 2019, 73, e13335.	1.7	61
22	Evaluation of the effects of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 285-292.	4.4	243
23	Concurrent variant type 3 autoimmune polyglandular syndrome and pulmonary arterial hypertension in a Japanese woman. <i>Endocrine Journal</i> , 2018, 65, 493-498.	1.6	3
24	Effect of growth hormone replacement therapy on plasma diacron-reactive oxygen metabolites and endothelial function in Japanese patients: The GREAT clinical study. <i>Endocrine Journal</i> , 2018, 65, 101-111.	1.6	13
25	Evaluation of a Premixed Insulin Analog Suspension in Japanese People with Type 2 Diabetes and the Clinical Importance of Improved Injection Techniques: A Cross-Sectional Pilot Study. <i>Diabetes Therapy</i> , 2017, 8, 445-449.	2.5	1
26	Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice. <i>Atherosclerosis</i> , 2017, 261, 44-51.	0.8	75
27	The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 743-751.	1.8	11
28	Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-naïve Japanese patients with type 2 diabetes: the TMD GÖT trial. <i>Diabetes Research and Clinical Practice</i> , 2017, 130, 237-243.	2.8	24
29	Impact of sex, fat distribution and initial body weight on oxytocin's body weight regulation. <i>Scientific Reports</i> , 2017, 7, 8599.	3.3	40
30	Circulating CD4+PD-1+ and CD8+PD-1+ T cells are profoundly decreased at the onset of fulminant type 1 diabetes and are restored by treatment, contrasting with CD4+CD25+FoxP3+ regulatory T cells. <i>Diabetes Research and Clinical Practice</i> , 2017, 133, 10-12.	2.8	16
31	Efficacy of Additional Canagliflozin Administration to Type 2 Diabetes Patients Receiving Insulin Therapy: Examination of Diurnal Glycemic Patterns Using Continuous Glucose Monitoring (CGM). <i>Diabetes Therapy</i> , 2017, 8, 821-827.	2.5	35
32	Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index. <i>Nagoya Journal of Medical Science</i> , 2017, 79, 9-16.	0.3	5
33	Effects of GLP-1 Receptor Agonists on Heart Rate and the Autonomic Nervous System Using Holter Electrocardiography and Power Spectrum Analysis of Heart Rate Variability. <i>Diabetes Care</i> , 2016, 39, e22-e23.	8.6	48
34	Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. <i>Diabetology and Metabolic Syndrome</i> , 2016, 8, 45.	2.7	154
35	Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study. <i>Cardiovascular Diabetology</i> , 2016, 15, 76.	6.8	32
36	Decreased glucagon levels and decreased insulin secretion after sitagliptin versus mitiglinide administration with similar glycemic levels following an oral glucose load: a randomized crossover pharmaceutical mechanistic study. <i>Diabetology International</i> , 2016, 7, 25-33.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2015, 110, 250-256.	2.8	35
38	Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34+CXCR4+ cells in patients with type 2 diabetes. <i>Endocrine</i> , 2015, 50, 659-664.	2.3	29
39	Bezafibrate, a peroxisome proliferator-activated receptor α agonist, decreases circulating CD14+CD16+ monocytes in patients with type 2 diabetes. <i>Translational Research</i> , 2015, 165, 336-345.	5.0	18
40	Liraglutide increases 24-h heart rate by reducing the cardiac parasympathetic activity of patients with type 2 diabetes: power spectral analysis of heart rate variability on 24-h Holter ECG recordings. <i>Diabetology International</i> , 2015, 6, 26-32.	1.4	3
41	Add-On Treatment with Tenziglipitin Ameliorates Glucose Fluctuations and Improves Glycemic Control Index in Japanese Patients with Type 2 Diabetes on Insulin Therapy. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, 840-845.	4.4	25
42	Epalrestat induces cell proliferation and migration in endothelial cells via mTOR activation through PI3/Akt signaling. <i>Diabetology International</i> , 2014, 5, 105-111.	1.4	1
43	The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes. <i>Translational Research</i> , 2013, 162, 309-316.	5.0	24
44	Spontaneous platelet aggregation evaluated by laser light scatter in patients with type 2 diabetes: Effects of short-term improved glycemic control and adiponectin. <i>Translational Research</i> , 2012, 159, 15-24.	5.0	15
45	Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. <i>Translational Research</i> , 2012, 159, 25-31.	5.0	70
46	Author reply. <i>Translational Research</i> , 2012, 160, 164.	5.0	2
47	Effects of retinol binding protein-4 on vascular endothelial cells. <i>Biochemical and Biophysical Research Communications</i> , 2011, 408, 58-64.	2.1	25
48	Determinants of Serum High Molecular Weight (HMW) Adiponectin Levels in Patients with Coronary Artery Disease: Associations with Cardio-renal-anemia Syndrome. <i>Internal Medicine</i> , 2011, 50, 2953-2960.	0.7	15
49	Relation between serum high molecular weight adiponectin and serum ferritin or prohepcidin in patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2010, 90, 250-255.	2.8	37
50	Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2009, 85, 147-152.	2.8	26
51	Serum high-molecular weight adiponectin decreases abruptly after an oral glucose load in subjects with normal glucose tolerance or impaired fasting glucose, but not those with impaired glucose tolerance or diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 1470-1476.	3.4	18
52	High-molecular-weight adiponectin does not predict cardiovascular events in patients with type 2 diabetes. <i>Translational Research</i> , 2009, 153, 199-203.	5.0	15
53	Anemia is associated with an elevated serum level of high-molecular-weight adiponectin in patients with type 2 diabetes independently of renal dysfunction. <i>Translational Research</i> , 2009, 154, 175-182.	5.0	29
54	Effects of Rosuvastatin and Colestimide on Metabolic Parameters and Urinary Monocyte Chemoattractant Protein-1 in Type 2 Diabetic Patients with Hyperlipidemia. <i>Southern Medical Journal</i> , 2009, 102, 361-368.	0.7	24

#	ARTICLE	IF	CITATIONS
55	Effects of losartan on serum total and high-molecular weight adiponectin concentrations in hypertensive patients with metabolic syndrome. <i>Metabolism: Clinical and Experimental</i> , 2008, 57, 1278-1285.	3.4	20
56	Role of retinol-binding protein 4 in the pathogenesis of Type 2 diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2008, 3, 161-173.	2.4	8
57	Cardiovascular Disease in Patients with Diabetic Nephropathy. <i>Current Molecular Medicine</i> , 2008, 8, 533-543.	1.3	24
58	Retinol Binding Protein-4 Levels and Clinical Features of Type 2 Diabetes Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2712-2719.	3.6	183
59	PPAR α Agonists Suppress Osteopontin Expression in Macrophages and Decrease Plasma Levels in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2007, 56, 1662-1670.	0.6	65
60	Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 2957.	3.0	122
61	High Molecular Weight Adiponectin as a Predictor of Long-Term Clinical Outcome in Patients With Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2007, 100, 569-574.	1.6	113
62	High serum high-sensitivity C-reactive protein concentrations are associated with relative cardiac sympathetic overactivity during the early morning period in type 2 diabetic patients with metabolic syndrome. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, 1014-1021.	3.4	37
63	Profound Reduction in T-helper (Th) 1 lymphocytes in Peripheral Blood from Patients with Concurrent Type 1 Diabetes and Graves' Disease. <i>Endocrine Journal</i> , 2006, 53, 377-385.	1.6	11
64	Fibrinolysis and diabetic vascular disease: roles of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor. <i>Future Lipidology</i> , 2006, 1, 429-440.	0.5	5
65	Synergistic Association of Metabolic Syndrome and Overt Nephropathy With Elevated Asymmetric Dimethylarginine in Serum and Impaired Cutaneous Microvasodilation in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2006, 29, 928-930.	8.6	10
66	Comparison of Serum High-Molecular Weight (HMW) Adiponectin With Total Adiponectin Concentrations in Type 2 Diabetic Patients With Coronary Artery Disease Using a Novel Enzyme-Linked Immunosorbent Assay to Detect HMW Adiponectin. <i>Diabetes</i> , 2006, 55, 1954-1960.	0.6	244
67	Metabolic Syndrome Accompanied by Hypercholesterolemia Is Strongly Associated With Proinflammatory State and Impairment of Fibrinolysis in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2005, 28, 2211-2216.	8.6	69
68	High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 345-350.	3.4	115
69	Elevated Pregnancy-Associated Plasma Protein-A in Sera from Type 2 Diabetic Patients with Hypercholesterolemia: Associations with Carotid Atherosclerosis and Toe-Brachial Index. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 5713-5717.	3.6	43
70	Results of Blood Inflammatory Markers Are Associated More Strongly With Toe-Brachial Index Than With Ankle-Brachial Index in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2004, 27, 1381-1386.	8.6	29
71	Adiponectin Concentrations in Sera From Patients With Type 2 Diabetes Are Negatively Associated With Sympathovagal Balance as Evaluated by Power Spectral Analysis of Heart Rate Variation. <i>Diabetes Care</i> , 2004, 27, 2392-2397.	8.6	47
72	Dissociation between urinary pyrroline and pentosidine concentrations in diabetic patients with advanced nephropathy. <i>Translational Research</i> , 2004, 144, 92-99.	2.3	18

#	ARTICLE	IF	CITATIONS
73	Coagulation and inflammation in overt diabetic nephropathy: association with hyperhomocysteinemia. Clinica Chimica Acta, 2004, 348, 139-145.	1.1	60
74	High plasma homocysteine concentrations are associated with plasma concentrations of thrombomodulin in patients with type 2 diabetes and link diabetic nephropathy to macroangiopathy. Metabolism: Clinical and Experimental, 2003, 52, 1517-1522.	3.4	15
75	Relationships of Plasma Interleukin-18 Concentrations to Hyperhomocysteinemia and Carotid Intimal-Media Wall Thickness in Patients With Type 2 Diabetes. Diabetes Care, 2003, 26, 2622-2627.	8.6	101
76	Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: Association with increased plasminogen activator inhibitor-1. Metabolism: Clinical and Experimental, 2002, 51, 471-476.	3.4	60
77	Relationship between soluble thrombomodulin in plasma and coagulation or fibrinolysis in type 2 diabetes. Clinica Chimica Acta, 2000, 301, 135-145.	1.1	32
78	Mechanisms of elevation of serum and urinary concentrations of soluble thrombomodulin in diabetic patients: Possible application as a marker for vascular endothelial injury. Metabolism: Clinical and Experimental, 1998, 47, 362-365.	3.4	23
79	Stiff-Man Syndrome Associated with Antecedent Myasthenia Gravis and Organ-Specific Autoimmunopathy.. Internal Medicine, 1997, 36, 308-311.	0.7	6
80	Parathyroid Carcinoma with Metastatic Calcification Identified by Technetium-99m Methylene Diphosphonate Scintigraphy.. Internal Medicine, 1996, 35, 392-395.	0.7	18
81	Effects of treatment with methimazole on circulating CD4 ⁺ and CD8 ⁺ T cells positive for programmed cell death protein-1 and on subsets of CD4 ⁺ T cells in untreated hyperthyroid patients with Graves' disease. Clinical Endocrinology, 0, , .	2.4	0